FYidoctors announces it has been named one of Canada’s Top Growing companies on the 2022 Report on Business annual ranking, unveiled this week. The organization earned its place on the prestigious list by generating a three-year growth rate of more than 65%. Moreover, it is the only company in the optical and eye care industry to make this year’s ranking.

One of the main growth drivers of FYidoctors and its Quebec-based banner, Visique, is its unique approach: doctor-led, professionally managed, and patient focused. Since its inception in 2008, the organization concentrates on delivering outstanding eye care along with patient-centric products and services. FYihealth group has grown to 400 locations in North America, with close to 700 Optometrist Doctors leading the evolution of eye care and eye health. FYidoctors ranked 399^th of a total 430 companies named to the 2022 list.

“We are so proud to be named to the list of Canada’s Top Growing Companies this year,” said Dr. Alan Ulsifer, Chair and CEO of FYihealth group. “We are excited for this achievement and the growth we have been able to achieve given the pandemic and the hyper-competitive environment of our industry. Our teams, whether at the home office or clinic levels, have shown incredible commitment, loyalty, resilience, motivation, and hard work—all of which has been instrumental to our success.”

Canada’s Top Growing Companies is an editorial ranking that was launched in 2019. It aims to celebrate the boldest entrepreneurial achievement by identifying and bringing the accomplishments of innovative businesses in Canada to the forefront. To qualify for this voluntary program; companies had to complete an in-depth application process and fulfill requirements.

The full list of 2022 companies along with editorial coverage is published in the October issue of Report on Business magazine. The list is out now and online here.

Click HERE for the press release.

Bausch + Lomb announced the presentation of one podium and two poster presentations at the World Cornea Congress VIII meeting, which will take place in Chicago from Sept. 28-29, 2022.

The podium presentation will feature findings from the pivotal Phase 3 trials of the investigational treatment NOV03 (perfluorohexyloctane), and the poster presentations will include pre-clinical data of NOV03 and data from Bausch + Lomb’s ongoing Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance study. The ARMOR study is the only ongoing surveillance study of its kind that evaluates profiles and trends in antibiotic resistance among common ocular bacterial pathogens across the United States.

“With the recent FDA acceptance of the New Drug Application for NOV03, we look forward to attending the World Cornea Congress so we can share valuable insights from our NOV03 clinical development program with the ophthalmic community,” said Christina Ackermann, president, Ophthalmic Pharmaceuticals, Bausch + Lomb. “We will also present findings from our unique ARMOR study, which for more than a decade has helped guide eye care professionals in selecting the most appropriate antibiotic treatment options to meet the needs of their patients.”

Following is a complete list of titles and lead authors for each of the presentations:

Podium Presentation

• “NOV03 for the Treatment of Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction: GOBI and MOJAVE Study Findings.” Tauber et al.

Poster Presentations

• “In Vitro Antibiotic Resistance among Bacterial Pathogens Sourced from the Cornea in ARMOR.” Asbell et al.
• “In Vitro Studies of Perfluorohexyloctane, an Investigational Eye Drop for Dry Eye Disease.” Borchman et al.
  
  
  Click HERE for the press release.